Epizyme reports interim Phase II data for tazemetostat in sarcomas
In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, Epizyme Inc. (NASDAQ:EPZM) reported interim data from a cohort of 31 evaluable patients with SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily b member 1 (SMARCB1; SNF5; INI1)-negative relapsed or refractory epithelioid sarcoma in a Phase II trial showing that twice-daily 800 mg oral tazemetostat (E7438, EPZ-6438) led to a disease control rate (DCR), the cohort’s primary...
Read the full 352 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Week In Review
Article Purchase
$35 USD
